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ABSTRACT 
In December 2019, a rare case of pneumonia was reported in Wuhan, China. This was later analyzed and known to have similar characteristics as 
viral pneumonia caused by a novel coronavirus. Later, on 11 February 2020, the World Health Organization (WHO) officially named the disease as 
COVID19. The Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) ought to taint both the upper respiratory tract and the lower 
respiratory tract. This COVID-19 is spreading quickly with an immense rise in cases around the world. This infection's mechanism stays obscure, 
and the medications explicit for the infection were not grown at this point. Infection is highly contagious. Severe Acute Respiratory Syndrome 
Coronavirus 2(SARS-CoV-2) is one of seven kinds of crown infection, including the one which causes severe maladies like Middle East respiratory 
disorder (MERS) and abrupt, intense respiratory syndrome(SARS). Since its revelation, the infection has spread and has caused anxiety and fear 
among people. Recent vaccines are tracked, and clinical trials can bring an immediate protocol on a medication approach. By including different 
therapeutic approaches, it is easier to combat the disease quickly. With very low mortality and high transmission rate, new approaches to vaccines 
and nanomedicines bring down the spread. Controlled patient care is also crucial. On 11 March, the World Health Organization (WHO) declared the 
disease as 'global pandemic’. COVID-19, therefore, poses a significant threat to global public health. 
This article reviews the epidemiology, pathogenesis, and diagnostic methods. The review also focuses on repurposed drugs, traced vaccines, and a 
quick view of prophylactic nanomedicines as an alternative for COVID 19. For this review, the complete database has been collected from various 
search engines such as PubMed, ScienceDirect, Scopus, Elsevier, etc., from the year 2001-2020 using the following keywords. 
Keywords: SARS-CoV-2, Covid-19, Infectious disease, Serology, Vaccine, Repurposing/repositioning drugs, Global pandemic, Cytokine storm, 
Pneumonia, Lung injury 
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INTRODUCTION  
COVID–19 is a world pandemic that affects human life and our 
livelihood [1]. Novel virus-induced coronavirus disease (COVID-19) 
was an outbreak that started in Wuhan, China [2]. However, the 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 
virus causes respiratory problems; however, this virus can spread 
through the air. The family of this virus can cause breathing illnesses 
in humans, in the form of common cold or pneumonia in addition to 
breathing infections [3-5]. The outbreak hastily grew and spread to 
the neighboring countries. Necessary action has been taken by the 
Ministry of Health and Family Welfare of India and raised awareness 
of the pandemic and managed the spread of COVID-19. The central 
and state governments have taken several measures and formulated 
several protocols to achieve their desired goal. India has not thrown 
off the pandemic, where it also gets dangerous. Medically adequate 
studies have been undertaken to solve this trouble worldwide [6]. 
Researchers are working day and night to acquire the vaccination 
for this single-stranded RNA, including viruses [7]. The present 
research has initiated people looking ahead to the prominent 
answers to clear up this pandemic threat. Perhaps, medical experts 
and wealthier people can assume vaccination. Prevent contagious 
spread and protect themselves by washing hands while coughing 
and sneezing, covering mouth and nose, and eating well-cooked 
meat and eggs. Reduce contact with people with respiratory 
symptoms. 
Epidemiology 
On 31 December 2019, the World Health Organization(WHO) 
Country Office in China reported pneumonia cases with unknown 
(causes) aetiology in Wuhan, Hubei Province, China. From 31 
December 2019 to 3 January 2020, the Chinese national authorities 
informed the World Health Organization of44 cases of pneumonia 
with aetiology being unknown. No cause was found for the 
occurrence of these cases of pneumonia during this reporting period. 
On 11 and 12 January 2020, the World Health Organization(WHO) 
received information from the National Health Commission China that 
exposure to a seafood market in Wuhan was associated with the 
spread. The Chinese authorities identified a new corona-virus causing 
pneumonia and isolated it on 7 January 2020. Furthermore, on 12 
January 2020, China publicized the genetic sequence/Genomic 
analysis data to other countries to engineer specific diagnostic kits. 
213 Countries and Territories around the world have reported 
confirmed cases of the corona-virus COVID-19 [8]. 
Transmission 
Respiratory infections can be spread through droplets. According to 
the evidence collected, the COVID-19 virus was transferred through 
droplets from the respiratory tract and interaction with people [9]. 
So it is essential to use personal safety events such as using masks 
and keep up social separation are some events taken to control the 
infection from an infected individual to non-infected individuals 
[10]. Respiratory droplet transmission occurs in case of close 
contact with people within 1 metre, with someone having 
respiratory symptoms like cold, coughing, sneezing, and they are at 
high risk of exposing their eyes, mouth, nose to infected respiratory 
droplets[11]. Transmission can occur by direct contact with an 
infected person or by indirect contact with the infected person's 
environment and substances [12]. Air bone spread is different from 
that of droplet spread as it refers to microbes in the droplet nuclei 
that can remain in the air for an extended time and can transmit 
within a distance of 1meter [13]. 
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Clinical features 
Covid19 manifestations can range from asymptomatic to severe 
septic shocks and multiorgan dysfunction. COVID-19 is classified 
based on the disease's severity from less severe symptoms to the 
most severe symptoms. The most common symptoms of patients 
include fever (98.6%), fatigue (69.6%), dry cough, and diarrhoea. 
For each individual, the effect of COVID-19 is different [14]. Most 
infected individuals show symptoms which can be cured without 
getting into hospitals. 
The most common symptoms include-fever, acne, dry cough, fatigue, 
diarrhoea, nausea, and sore throat. 
Less common symptoms include-discoloration of the skin, rashes on 
fingers, loss of taste or smell, pain, and headaches. 
Severe symptoms include-breathing difficulty, shortness of breath, 
pain, or pressure on the chest, loss of movement. Usually, it takes an 
average of 14 d to show symptoms, and usually 5-6 d to get infected 
[15]. 
Diagnosis 
COVID 19 diagnosis is vital and essential. Due to the extreme spike 
in more than 100 countries, identifying infected persons with Severe 
Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) helps 
guide those individuals in terms of treatment and indicates who 
needs to be isolated. They have their contacts traced and identified. 
This prevents the further spread of the disease and promotes 
effective infection control. Even if a vaccine is developed, diagnostic 
testing is critical to ensure that the vaccine is used as effectively and 
efficiently as possible. It also indicates those who are at high risk of 
coronavirus and those infected who are fully recovered. 
Diagnostic tests depend on viral load in the upper and lower 
respiratory tract. 
Two major tests are 
1. Viral test. 
2. Serological test. 
Other tests include Computed Tomography(CT) scan, Magnetic 
Resonance Imaging(MRI) scan, or checking body temperature or 
checking low oxygen levels. 
Tests are done to check for current infection and the possibility of 
past infection. 
Viral load test 
This test is done to check if the patient has a current infection. 
Early screening or diagnosis of infection is often recommended 
before the 6th day of developing symptoms. Here a nasopharyngeal 
swab or an or pharyngeal swab is taken as a specimen. These 
specimens contain high viral loads. Swabs should be kept in place for 
10s while being twirled three times. To the nasal cavity, the swab is 
inserted deeply [16, 17]. 
Laboratory analysis thereby takes 1-2 d after specimen collection. 
Rectal swabs can also be used to detect the Severe Acute Respiratory 
Syndrome Coronavirus 2(SARS-CoV-2) in stool and their recurrent 
shedding. This helps in monitoring of patients in terms of infectivity 
and cure [18]. Positive results are accurate, but there is a high 
chance of negative results, which does not rule out infection. If the 
viral test is negative, it does not mean a person was not infected 
with the virus but infected at an early period and may not show any 
signs of infection during the time of testing. In such cases, an 
antibody test is done, which indicates past infection. 
Serology test 
Antibodies are disease-specific, and this test helps detect antibodies 
corresponding to virus antigens present in the blood. Various 
serology tests are specific, and the antibodies are detectable only 
after 10-14 d after the infection (mainly the presence of 
Immunoglobulin G antibodies(IgG)). The average peak is 28 d after 
the initial onset [19]. Serological methods are mainly used to find 
out S protein, which is an antibody against coronavirus. This spike 
determines host tropism and transmission capability. 
Immunoglobulin M(IgM)and Immunoglobulin G(IgG)are the two 
primary antibodies produced against the antigens in response to 
infection. Results produced if positive, then treatment should be 
initiated immediately, and persons must be careful without 
spreading the disease. There is also a chance of having viruses of the 
same family as that of coronaviruses. If the test results are negative, 
then the person may not have developed any antibodies but can 
have infection and chances of developing antibodies in later stages. 
In 30 percent of cases, there is a chance of antibodies on the 7th
Pathogenesis 
 day 
of the infection [20]. 
Pathology varies among adults and children. Infectivity of Severe 
Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2) is much 
higher than Severe Acute Respiratory Syndrome Coronavirus 
1(SARS-CoV1) [21]. As per clinical, immunological progression, the 
disease progresses in 3 different phases that include a flu-like phase 
with high viral load, a critical phase which includes viral response 
(lung and lung injury), and the recovery phase. In elderly persons, 
cytokine expression is highly increased and is followed by 
consecutive overactivity of innate immunity followed by virus-
induced cell injury. Various Immune mechanisms include trained 
immunity, cross-immunity to coronavirus infection, developmental 
changes in immunity, and repair of inflammatory lung damage are 
some protective mechanisms involved. 
COVID-19 disease is caused by the pathogen beta-coronavirus, 
whichbelongs to the genera of the coronaviridae family. 
Pathogenesis is similar to Severe Acute Respiratory Syndrome 
Coronavirus 1 (SARS-CoV1) and the Middle East Respiratory 
Syndrome Coronavirus(MERS-CoV), respectively [22]. Severe Acute 
Respiratory Syndrome Coronavirus 2(SARS-CoV-2) consists of an 
envelope with a positive-sense single-stranded RNA virus from the 
beta coronavirus. The surface spike proteins give a crown-shaped 
structure on electron microscopy. Alpha and beta coronaviruses 
mainly affect mammals among the four different genres, such as the 
alpha, beta, gamma, and delta coronavirus [23].  
Coronavirus mainly consists of 4 parts, the spike, envelope, 
membrane, and nucleocapsid [24]. Spikes defines the host tropism. 
Spike comprises two main subunits S1 and S2. S1 subunit binds to 
the host cell receptor while the S2 subunit fuses to viral and cellular 
membranes. Angiotensin-Converting Enzyme 2 (ACE2) is the 
primary functional receptor for Severe Acute Respiratory Syndrome 
Coronavirus (SARS-CoV). Angiotensin-Converting Enzyme 2 (ACE2) 
receptors are mainly present in the lungs, heart, kidneys, ileum, and 
bladder [25]. Virus entry is through proteolytic cleavage at the 
Angiotensin Converting Enzyme (ACE) receptor binding site mainly 
by transmembrane serine protease 2. Once the virus enters through 
the nasal cavity or the oral route to the epithelial cells of the nasal 
cavity and starts replicating. This state is called an asymptomatic 
state where the viral load is very low and is the initial infection 
phase. Furthermore, the virus can be detected by nasal swabs [26]. 
Once spike protein binds to the host protein, it undergoes protease 
cleavage and activates spike proteins. Entry is by direct membrane 
fusion. Cleavage mainly occurs at the S2 site [27]. 
The virus then propagates to the lower respiratory tract, and an 
innate immune response is triggered. Immune response mainly 
includes C-X-C Motif Chemokine Ligand 10 (CXCL10) beta and 
lambda interferon’s, which act as disease markers in SARS. Antigen 
presentation is followed by subsequent stimulation of humoral and 
cellular immune responses, which is later mediated by virus-specific 
B cells and T cells [28]. Most of the infected patients are affected at 
the upper respiratory tract, and patients are monitored at home, 
giving symptomatic therapy. Lymphopenia is a clinical presentation 
at the initial stages. 
On the progression of the disease 
Disease progression is characterized by pulmonary infiltrates and is 
mainly seen in aged persons at high risk. The virus then reaches the 
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lungs' gas exchange units, affecting alveolar type 1 and type 2 
epithelial cells [29]. A large number of virus particles are released, 
and the cell undergoes apoptosis. Self-replicating pulmonary toxins 
are released subsequently. The patient then shows symptoms of 
acute respiratory distress syndrome (ARDS). The process is then 
followed by a cytokine storm which includes a spike in an 
uncontrolled systemic inflammatory response which involves the 
deadly release of pro-inflammatory cytokines that provides for 
interferons (IFN) such as (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-
33, TNF-α, TGFβ) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, 
CXCL10) immune effector cells in Severe Acute Respiratory 
Syndrome Coronavirus (SARS-CoV) infection.In patients with severe 
disease, pathogenic CD4+T cells with co-expressing interferon (IFN)-
γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
were seen in COVID-19 patients. Granulocyte-Macrophage Colony-
Stimulating Factor (GM-CSF) can initiate tissue damage to high 
levels [30]. Many inflammatory cells were also seen on lung surfaces 
of severely infected patients, followed by scarring and fibrosis. 
Angiotensin-Converting Enzyme 2 (ACE2) receptors are significantly 
expressed on innate immune cells that are Group 2 and Group 3 
Innate Lymphoid Cells (ILC2and ILC3). Multiple organ failure and 
finally, death results in severely ill COVID 19 infection patients [31]. 
Therapeutic management approach 
Therapeutic management using repurposing or repositioning of drugs. 
Repurposing/repositioning of drugs 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2) is a 
novel virus disease, it is tough to get new medicines and vaccines 
quickly, and the condition worsens. Knowing the pathophysiology 
very similar to Severe Acute Respiratory Syndrome Coronavirus 
1(SARS-CoV-1)and the Middle East Respiratory Syndrome 
Coronavirus(MERS), getting new medicines having exact drug 
targets is very difficult and needs many studies and research. Hence, 
for an immediate cure, knowing about each of these drugs' 
mechanisms of action makes it easier for immediate therapy but not 
recommended every time due to its high toxicity. Some countries are 
against using these drugs, but some use them after many clinical 
studies. The Discovery of new medicines and their preclinical to 
phase 3 trials are often time-consuming and require many 
procedures. Hence, using these repositioned medicines is an 
effective strategy in managing therapeutic approaches and 
minimizing its toxicity[32]. These drugs have often been known to 
humans for past years, need just quick evaluation, and are readily 
available. Safe vaccination is highly recommended for this infection 
but not available soon in the COVID 19 outbreak. The virus also 
undergoes mutations as it progresses; hence, it is difficult to find 
new drug targets. Therefore repurposing drugs has made the 
therapeutic approach much more manageable, and the management 
of the disease is done appropriately without delay. There are many 
medications used now for repurposing, as shown in table 1. 
 
Table 1: Classification of drugs based on their class 
Drugs Class Reference 
1. Chloroquine and Hydroxychloroquine Antimalarial Drugs [33] 
2. Lopinavir and Ritonavir Antiviral Drugs-Protease Inhibitor 
3. Nafamostat and Camostat Protease Inhibitor-Protease Inhibitor 
4. Umifenovir Antiviral Drugs 
5. Nitazoxanide Antiprotozoal 
6. Ivermectin Anthelmintics 
7. Corticosteroids Steroid Hormone 
8. Tocilizumab and Sarilumab Interleukin-6 Blockers 
9. Bevacizumab Antiangiogenic Agents 
 
Repurposed drugs 
Chloroquine and hydroxychloroquine 
Drugs for COVID 19 virus for repurposing are divided into two 
categories: the one targeting the replication cycle and one that 
controls the disease's symptoms. The polymerase inhibitor 
aminoquinolinesChloroquine (CQ) and Hydroxychloroquine(HCQ) 
are used as antimalarial therapy. There is an accumulation of toxic 
heme in parasites because the antimalarial drugs inhibit heme 
polymerase, leading to death. In the case of COVID-19, drugs will 
keep the virus away from the host cell by lysis of the host receptor's 
glycosylation and break down viral protein production by inhibiting 
endosomal acidification in vitro [34]. The benefit is attributed to the 
well-known lysosomotropic property of the drug and Interferes with 
ACE2 receptor glycosylation and the autophagic process, thereby 
blocking the viral attachment and entry. The first documented 
report was from China; Hydroxychloroquine(HCQ) was more potent 
and safer than Chloroquine(CQ), which was the concluding 
statement. Hydroxychloroquine(HCQ) was more potent than 
Chloroquine(CQ) to inhibit Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2), and the combination of 
Hydroxychloroquine(HCQ) with Azithromycin in patients with 
COVID-19 led to a decline in COVID-19 mortality [35]. Chloroquine 
(CQ) showed remarkable results both in terms of clinical outcome 
and viral clearance compared with the control group. Treatment, in 
combination with Azithromycin, appeared to induce conduction 
disorders and increased Cardiovascular(CV) mortality. 
Chinese researchers found that chloroquine is highly useful and 
effective in reducing the viral replication that can be achieved by 
standard dosing due to its penetration into tissues, including the 
lungs [36]. The only difference between chloroquine and 
hydroxychloroquine is the hydroxyl group at the terminal. Both are 
weak bases, leading to a change in the PH of intracellular organelles 
that is acidic and is vital for the fusion of membranes. It is learned 
that antiviral and anti-inflammatory action is essential in the COVID 
19 treatment [37]. Chloroquine(CQ) and Hydroxychloroquine(HCQ) 
have been used to reduce symptoms duration, exacerbation of 
pneumonia. So this led to including chloroquine and 
hydroxychloroquine in prevention and treatment [38]. A trial for 
Hydroxychloroquine(HCQ) was conducted in France and it was 
found that Hydroxychloroquine(HCQ) when used alone or in 
combination with Azithromycin was effective in clearing viral 
nasopharyngeal carriage. (Measured by Polymerase Chain Reaction 
(PCR)).This shows the synergistic effect of Azithromycin with 
Hydroxychloroquine(HCQ) [39]. While using these drugs, some 
precautions must be taken, monitoring hematological parameters 
(Red Blood Cell(RBC), White Blood Cell(WBC), and platelet counts), 
serum electrolytes measurement, blood glucose, hepatic, and renal 
function [40]. The World Health Organization (WHO) removed the 
above drugs by accepting solidarity trial recommendations 
formulated by the Solidarity trial interim committee. However, 
Solidarity clinical trials were not done in pre and post-exposure 
patients, hence it could be beneficial for pre and post-exposure 
prophylaxis. 
Lopinavir and ritonavir 
Lopinavir and Ritonavir are new classes of drugs that work by 
inhibition of 3 chymotrypsin-like proteases and papain-like 
proteases, and it comes under the protease inhibitor category. 
For the infection of the virus, no therapeutic agents are known. 
However, as these proteases cleave at various polypeptides, thereby 
producing individual functional proteins such as RNA-dependent 
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RNA polymerase(RdRPs) andNon-Structural Proteins(NSPs), this 
process is also inhibited, blocking the replication process [41]. 
Lopinavir is a protease inhibitor that acts by inhibiting the viral 
target molecules [42]. By inhibiting cytochrome p450 enzyme, it can 
increase the plasma half-life of the drug and is usually done by a 
combination of Ritonavir and Lopinavir. A combination has also 
improved efficiency.  
A study done in 2004 shows a decrease in acute respiratory distress 
syndrome by combining ribavirin with Lopinavir-Ritonavir and 
reducing death [43]. 
Some random clinical trials show that drugs given in combination 
are more effective than standard care because the drug's side effects 
have limited appeal. Significant side effects include liver damage, 
nausea, and diarrhoea [44]. There is also a risk of QT prolongation 
and cutaneous reactions. According to the National Institute of 
Health’s(NIH) updated information, a randomized, double-blind, 
placebo-controlled clinical trial was conducted on 4000 participants. 
It was a Multi-centric, Phase 2-like, investigator-directed trial, where 
hospitalized adult patients with laboratory-confirmed Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection 
provided information based on the trial and offered enrollment[45]. 
The World Health Organization(WHO) in July discontinued the use 
of the above drugs by accepting recommendations from the 
Solidarity Trial's International Steering Committee. 
Nafamostat and camostat 
Nafamostat and camostat were used for pancreatitis in japan, which 
comes under serine protease inhibitors. Previously camostat acted 
as an antagonist to serine protease to block the entry of Severe 
Acute Respiratory Syndrome Coronavirus (SARS-CoV), and it is said 
that camostat and nafamostat have a similar action in inhibiting 
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).  
Its primary target molecule is Transmembrane Protease Serine 
2(TMPRSS2). According to the reports obtained from an 
experimental study in Japan for efficient fusion of Severe Acute 
Respiratory Syndrome Coronavirus (SARS-CoV 2) into the infected 
human cell, both the receptors' expression is required. Results also 
reported that Nafamostat was tenfold more potent than 
Camostatmesylate and had themost significant activity compared to 
camostatmesylate. Later studies also reported that nafamostat has 
higher efficiency in inhibiting the viral cell entry, almost 15 folds 
higher than camostat. Namostat and Camostat have undergone 
various clinical trials for COVID 19 in the United States of America 
(USA) and Japan [46]. 
Umifenovir 
Central Drug Research Institute (CDRI), a lab in India–primarily 
based Council of Scientific and Industrial Research (CSIR), has got 
approval for using Umifenovir for the Phase III trial. In this 
randomized, double-blind, placebo-controlled trial, Central Drug 
Research Institute(CDRI) will test the efficacy, protection, and 
tolerability of Umifenovir. 
According to the statement by the government: "This drug has a 
good protection profile and acts through stopping access of viruses 
into human cells and also with the aid of priming the immune 
system." 
Umifenovir, a drug used to treat influenza, was readily available in 
China and Russia, and this drug can also be used for treating COVID-19 
patients. CSIR-CDRI is conducting this trial to examine its efficacy in 
Indian patients. CSIR–CDRI has evolved the manner generation for 
Umifenovir[47]. Umifenovir was first used in Russia and China to treat 
influenza viruses A and B. The drug comes under the category of 
indole–derivative. By the assessment of lopinavir/ritonavir, it was said 
to be effective against the virus. A new trial observed treatment to be 
less potent for people with mild COVID-19. 
Nitazoxanide 
Nitazoxanide, an anti-parasite drug used to treat cryptosporidiosis 
and giardiasis, each parasite causes diarrhoea and some anaerobic 
bacteria, viruses, and different protozoa. It is rapidly metabolite 
Nitazoxanide, which has not been examined for its interest against 
Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) as 
yet. However, it does show in vitro activity, like nitazoxanide, against 
the influenza virus and another coronavirus, rotaviruses, and the 
hepatitis B and C viruses. It may reduce the symptoms and shedding 
of SARS-CoV-2, and improve the innate immune responses, 
increasing interferon type 1 production. It additionally blocks 
TMEM16A ion channels and so causes bronchodilation. It is 
relatively safe, with minimum unfavorable gastrointestinal effects 
when given as a single oral dose at up to 4 grams.It is advocated to 
be taken after food, as this will increase the plasma levels. 
An ongoing clinical trial is anticipated to provide records on the 
interest of Nitazoxanide at a dose of 500 mg twice daily(BD), either 
alone or at the side of Hydroxychloroquine(HCQ), in opposition to 
SARS-CoV-2. However, there is no publicly available assisting 
evidence for this dose against the virus [48]. 
Ivermectin 
Ivermectin is a drug that can treat many diseases because of its 
antimicrobial, antiviral, and cancers. It is enormously influential 
towards many microorganisms which have some viruses. Different 
studies on ivermectin show its antiviral effects on RNA viruses, 
which carries with it Zika, dengue, infectious disease, and severe 
acute respiratory syndrome coronavirus 2 [46].Ivermectin acts as a 
character in various organic mechanisms, consequently being 
inclusive of COVID-19 as different kinds of high-quality on single-
stranded RNA viruses [49]. 
Ivermectin is used as an antiparasitic drug that may influence 
invertebrates and is typically a lipophilic macrolide. Ivermectin acts 
by binding to glutamate-gated chloride ion channels in parasites, 
leading to paralysis or loss of life of the parasite. It is assumed to 
bind and destabilize Severe Acute Respiratory Syndrome 
Coronavirus(SARS-CoV) cells and transport proteins that enter the 
nucleus. In an observational study, the administration of ivermectin 
will lead to a low death rate. With a minimum of trials are presently 
recruiting members to check the efficacy of the drug [50]. 
Corticosteroids 
Researchers are trying to reduce the potential cytokines storm that 
leads to respiratory injury and acute respiratory distress syndrome 
in people. In conjunction with effectiveness, one of the main 
concerns is the safety of these medications. Also, this drug has 
chances of other infections related to the disease. It is chief among 
the immunomodulatory drugs. These are well studied but have cases 
of adverse reactions. Some molecules inhibit gene expression, which 
codes for inflammatory molecules. Nevertheless, long term use can 
cause bone density loss. A previous report says corticosteroids 
provide a risk of higher mortality in those with influenza pneumonia 
[51].  
Tocilizumaband sarilumab 
These are immunomodulatory mediators and are Interleukin-6(IL-
6)alpha inhibitors commonly used for severe COVID-19 patients. A 
double-blind placebo-controlled phase 3 clinical trial evaluates the 
safety and efficacy of Tocilizumab. Tocilizumab could treat about 
75% of patients and out of which most of them required mechanical 
ventilation, oxygenation, and inflammatory biomarkers. Moreover, 
the treatment also showed very high survival rates. They are mainly 
used to reduce the risk of cytokine storm in covid19 infection. 
Usually used to treat rheumatoid arthritis, Covid-19, it acts in 
vivoand reduces clinical symptoms of viral infection. It is also an 
immunosuppressive. Some Chinese studies proved that patients 
with COVID 19 (15 of 20) treated with Tocilizumab have reduced the 
use of oxygen supplements and showed that fever reduces rapidly. 
For 21 patients, another trial was carried out in China using the 
Interleukin-6(IL-6) receptor antibody, Tocilizumab, which several 
companies identified to understand the effectiveness against SARS-
CoV-2. Toxicity includes high toxic erythema and eosinophilia, but 
no clear cases until now have been founded. 
Sarilumab is also another Interleukin-6(IL-6) inhibitor that plays a 
significantrole in the overactivity of inflammatory response. It is also 
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used as an antirheumatic drug. Again it is used for the treatment of 
severely ill patients. A phase 3 trial was done by US Company 
Regeneron, Sanofi, in Covid-19 patients. On elevated levels of 
Interleukin-6(IL-6), repeated doses of either are recommended. 
Primary toxicities include opportunistic infections and hematologic 
toxicity, but no cases have been found until now [52]. 
Bevacizumab 
Bevacizumab is an anti-VEGF recombinant humanized monoclonal 
antibody, which has been used as an anti-tumour agent. Evidence 
suggests that Bevacizumab is the best drug for severe and critical 
COVID-19 patients. It mainly reduces Vascular Endothelial Growth 
Factor(VEGF) levels caused by hypoxia, severe inflammation, and 
increased respiratory tract epithelium, which is infected. This drug 
might suppress edema in patients with COVID-19. 
It is therapeutically useful in Acute Lung Injury (ALI) and Acute 
Respiratory Distress Syndrome (ARDS) due to increased vascular 
permeability and induces in pulmonary oedema. The drug is widely 
used in clinical immunotherapy. In critical COVID-19 patients, it 
decreases mortality. Common adverse reactions include edema, 
fatigue, diarrhea, and abdominal pain. It was also used in the 
treatment of dyspnea symptoms [53]. 
 
Table 2: Tracking of some Covid19 vaccines 
Candidate Vaccine type and characteristics Trial phases Institution Reference 
1. AZD1222 Chimpanzee adenovirus vector vaccine contains 
the gene that codes for SARS-CoV protein. 
Phase 1 The University of Oxford,the Jenner 
institute. 
[54] 
2. MRNA-1273 RNA Vaccine, lipid nanoparticles contain the 
mRNA encoding the SARS-CoV2 S protein. 
Phase 2 Kaiser Permanente Washington 
health research institute. 
3. BNT162 RNA Vaccine-lipid nanoparticles contain the 
mRNA encoding the SARS-CoV2 protein. 
Phase1/2 Multiple study sites in Europe. 
4. INACTIVATED D-
VACCINE 
Virions inactivated with chemicals or 
radiation,without adjuvant, rendering the viral 
genome noninfectious. 
Phase1/2 Henan provincial center for disease 
control and prevention. 
5. BBIBP-CORV 
 
Inactivated virus vaccine. Phase1/2 Henan provincial centre for disease 
control and prevention.  
6. IND-4800 DNA plasmid encoding the SARS-CoV-2 S protein 
delivered by electroporation DNA vaccine. 
Phase 2 Centre for Pharmaceutical research, 
Kansas city University of 
Pennsylvania, Philadelphia. 
7. CORONAVAC Inactivated Vaccine with alum. Phase 2 
 
Sinovac research and developing 
Co., Ltd. 
8. NVX-COV2373 Protein subunit, full length recombinant SARS-
CoV-2 glycoprotein nanoparticle vaccine 




Vaccines are now crucial to prevent the transmission of the disease 
and to prevent the individuals from infection of Severe Acute 
Respiratory Syndrome Coronavirus 2(SARS-COV-2). Many vaccines 
are generated against the SARS-COV-2, for example, DNA and RNA 
based vaccine, inactivated virus vaccine, viral vector vaccine, 
recombinant protein vaccine, and live attenuated vaccine. According to 
the recent update from the World Health Organization(WHO), there 
are almost 100 vaccines in their development process at various 
phases, and ten vaccines are under evaluation at the clinical level. 
The mRNA type vaccines were given to the infected patients that 
contain mRNA oligonucleotides that encode antigen of interest. The 
advantage of this type of vaccine is that it can mimic infection 
occurring naturally and provide an excellent immune response [55]. 
The Vaccine Research Center, a unit of the National Institute of 
Allergy and Infectious Diseases (NIAID) and Moderna,have started 
developing an mRNA vaccine for COVID 19. Moderna works with the 
FDA and both government and non-government agencies and is now 
in phase 2 of development. Other mRNA vaccine makers, such as 
those by BIONTech and Pfizer, are also under different vaccine 
development phases [56]. DNA vaccines are more accurate for 
infectious diseases. Various DNA vaccines use electroporation to 
bring plasmids and attach adjuvant to improve the immune function. 
Inovio Pharmaceuticals are developing COVID 19 DNA vaccine to 
protect from Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-COV-2). It acts by inducing the activation of the T cell by 
bringing plasmids that express Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) protein [57]. Viral vector vaccines are 
mainly present in the host body as its genetic material, leading to 
infecting the antigen-presenting cells, leading to the induction of 
both B cells and T cells. CanSinoBIO and Beijing Institute of 
Biotechnology(BBI) develop a viral vector vaccine [58]. Being an 
inactivated virus vaccine, this type of vaccine works by chemicals 
such as formalin or heat that maintain the virion structure and 
preserve its antigenicity and eliminate the potential that causes the 
infection. Such a type of vaccine was useful and was safe for 
preventing the poliovirus and influenza virus. Wuhan Institute of 
Biological Products and The Beijing Institute of Biological Products 
are developing an inactivated virus vaccine for COVID-19. 
Other vaccines developed, such as the live-attenuated vaccine, work 
by eliminating or reducing the virus's virulence using chemicals. 
This type of vaccine gives lifelong protection and is not much 
expensive. Codagenix and the Serum Institute of India developed a 
live attenuated vaccine against COVID-19. Recombinant protein 
vaccine has an advantage over other types based on their safety, and 
side effects are very few, and without introducing the virus, it 
induces an immune system. The NVX-CoV2373 vaccine developed by 
Novavax is an example of a recombinant protein-based vaccine [59]. 
Use of prophylactic nanomedicines as an alternative for  Covid-19 
Just like other pneumonia-like infections in this case also, the virus 
mainly targets the lung. Most of the vaccines and medicines that 
have been brought through repurposing mainly focus on 
neurological and haematological complications observed during 
advanced stages of the disease [60].The target of this viral infection 
is mainly lung and respiratory cells. Biomedical devices thereby help 
in the easy procurement of compact medicines which are target 
specific and have improved efficacy and safety [61].It is a simple 
therapeutic approach and is done by considering the known 
medicines as lead molecules in which efficacy is enhanced by using 
other molecules. Lead molecules can interfere in this RNA 
polymerization using the interference approach, and the dose-
dependent effect of any molecules can be controlled by exploring 
conjoining pathways or a combination of molecules. Lead molecules 
used are generally of those that can quickly be diffused through the 
nuclear membrane and switch the RNA processes. Viral replication 
can be thereby controlled using such molecules. Such molecules 
have similar acid-baseequilibria to that of nucleic acid bases leading 
to nonspecific inhibition of DNA/RNA polymerization, which even 
modulates mutation [62]. This then narrows the pathway making it 
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specific to organ/tissue/cells as targeting approaches. Metered 
devices such as inhalers are then used for targeted drug delivery to 
the lungs. Antimicrobial functions can be induced by self-dividing 
nanoparticles with catalytically active surfaces engineered with drug 
carriers that are target specific and involve conjoining the pathways. 
Prophylactic drugs developed are of two types: the new drug lead 
and another for reducing the primary lead molecule dose. As 
explained above, an example of such a mechanism includes using 
pyridoxine with nicotine, theophylline, and caffeine that reduces the 
pH, thereby suppressing nucleic acid polymerization; they also 
modify the dose. Such molecules have specific receptor-mediated 
activities like competitive inhibition for suppressing viral binding 
and replication. Therefore, advances in pulmonary medicines should 
be modified so that they can deliver such medicines in a simplified 
manner. Moreover, the delivery is done either in a single route or 
through multiple route administration such that prophylactic 
concentration is procured. Therefore, this expands the approach of 
new medicinal applications. These applications are also valid for 
developing broad-spectrum antivirals for many viral infections 
other than Covid-19 that can mainly affect the lungs [63]. 
Steps to be taken by people and patient care 
Protect ourselves and people around us by making aware of the 
situations and taking needed measures as precautions. Follow all the 
guidelines given by the Indian health authority. 
To stop the transmission of the virus:  
● To kill the virus present in the hand, wash the hands frequently 
with soap and water or use an alcohol-based hand rub [64]. 
● Maintain a safe distance from coughing and sneezing people 
because when they cough or sneeze, sometimes fine droplets are 
sprayed from the infected person to non-infected ones in which the 
droplet may contain the virus. If people stand too close to the 
infected when they breathe, the virus may directly get into the body 
of the non-infected people. 
● It is recommended to wear a mask in public because if people 
come closer to someone having the coronavirus, they can infect the 
non-infected individual [65]. 
● Do not touch the eyes, nose, or mouth, which may take up the 
virus present in the hands. When the hand is contaminated with the 
virus, it can directly spread from the eyes, nose, or mouth to the 
body and cause infection [64]. 
● W hile coughing or sneezing, take a towel and cover the nose or 
mouth and dispose of it after use. We can protect people around us 
by following good respiratory hygiene. 
● If minor respiratory symptoms are seen, be at home and take rest 
until recovery. 
● In case of any respiratory symptoms or fever, ask for medical help 
as soon as possible, call them because it helps to get the right and 
timely health facilities. This will also help to prevent the spreading 
of the disease to our dear ones. 
Calling the medical team in advance can quickly direct the patient to 
the right health facility. This protectspeople around the infected 
ones and prevents the spread of the virus and other infections. 
Shaking hands and coming in close contact can transmit the virus 
due to its high transmission rate and avoid close contact. 
Sharing personal items like clothing, phones, utensils, and other 
items can transmit viruses rapidly; hence should be restricted. 
● Clean and disinfect surfaces like door handles, furniture, toys, and 
clean commodities like a laptop, phone, etc., which has regular use in 
a day. 
● Avoid eating and drinking in public places–the virus can transmit 
through food utensils, dishes, and cups [65]. 
Health care workers who care for individuals with infection should 
try to utilize Personal protective equipment(PPEkits) containing 
masks, eye protection, gowns, and gloves, which are safety measures 
that prevent transmission of the virus. 
Isolation and contact tracing alone cannot control the spread of 
disease. Hence people should coordinate accordingly, listen to 
government officials and healthcare personnel, give them less stress, 
and tackle the outbreak more efficiently [64]. 
CONCLUSION 
The novel coronavirus spread so rapidly that it has changed the 
rhythm of the world. The use of repositioned medicines helps in 
managing the rapid disease spread. The specificity of drug 
repositioning drug molecules brings about effective disease 
management and strategic treatment protocol. However, 
Chloroquine, Hydroxychloroquine, Lopinavir, and Ritonavir have 
been discontinued, but existing clinical trials are going on for 
prophylaxis and early-stage treatment. Nafamostatmesylate and 
Favipiravir have greater chances due to its peculiarities in inhibition 
of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). 
The remaining drugs that include Famotidine, Umifenovir, 
Nitazoxanide, Tocilizumab, Sarilmumab, and Corticosteroids, have 
shown better clinical outcomes. However, clinical trials are still 
ongoing. Also, acceptance of Solidarity clinical trial 
recommendations is crucial before the release of the drugs. 
Vaccine developments are running at various stages, and human 
trials possess many difficulties and are often time-consuming. 
Advancement in pulmonary medicine and the development of 
prophylactics by nanoparticles can improve the management 
protocol efficiently. As many institutes are involved, many ethical 
issues arise and can have many conflicting interests. Hence there is 
hope for these treatment managements to be a breakthrough in 
current medicine, as supportive therapy is the need. Also, safety 
measures should be taken care of, and protocols should be followed 
for immediate relief. 
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